JPRN-UMIN000015258尚未招募未知
A feasibility study of capecitabine plus oxaliplatin (CapeOX) and S-1 plus oxaliplatin (SOX) for unresectable advanced or reccurent gastric cancer - A feasibility study of capecitabine plus oxaliplatin (CapeOX) and S-1 plus oxaliplatin (SOX) for unresectable advanced or reccurent gastric cancer
Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital0 个研究点目标入组 40 人开始时间: 2014年9月29日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients are excluded if they have HER-2 postive adenocarcinoma. HER-2 positivity is defined as IHC 3+ or IHC2+ and FISH-positive(HER2:CEP17 ratio over 2). Other exclusion criteria included uncontrolled infection, or uncontrolled significant comorbid conditions.
研究者
相似试验
已完成
2 期
A feasibility study of capecitabine and oxaliplatin (XELOX) for patients with stage II/III colon cancer.colorectal cancerJPRN-UMIN000008029Japanese Foundation for Cancer Research36
已完成
不适用
Phase II study of Capecitabine + oxaliplatin(CapeOx) for elderly patients with untreated metastatic gastric cancer <TCOG GI-1601>ntreated metastatic gastric cancerJPRN-UMIN000022450The Tokyo Cooperative Oncology Group110
已完成
不适用
A phase II study of capecitabin plus oxaliplatin therapy (XELOX) for inoperable/advanced gastric cancer resistant/intolerable to fluoro-pyrimidine, CDDP, Taxane or CPT-11 (OGSG1403)unresectable/advanced gastric cancerJPRN-UMIN000016256Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)12
已完成
2 期
P II study of CapeOX therapy for small intestinal cancerunresectable or recurrent small bowel adenocarcinoma with no prior treatmentJPRN-jRCTs041180011Yasui Hirofumi17
招募中
4 期
Cohort study of capecitabine plus oxaliplatin (XELOX) together with Bevacizumab as the first-line therapy in advance or recurrent colorectal cancer.Advance or recurrent colorectal cancer.JPRN-UMIN000006057Tokyo Medical University The third department of surgery30